Is Crop Life Scienc overvalued or undervalued?

As of 16 September 2025, the valuation grade for Crop Life Science has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 15.59, an EV to EBITDA of 8.83, and a ROCE of 11.07%.
In comparison to its peers, Crop Life Science's PE Ratio is significantly lower than that of P I Industries, which stands at 35.02, and Bayer CropScience at 39.94, both categorized as very expensive. Meanwhile, UPL, which is rated attractive, has a PE of 35.19, suggesting that Crop Life Science may be positioned well within its industry despite the recent downgrade in valuation grade. Additionally, the company's stock has outperformed the Sensex year-to-date, with a return of 20.04% compared to the Sensex's 6.74%, reinforcing its competitive standing in the market.